There is no registration fee for this event. For the in-person symposium in Chicago, preregistration is required as seating is limited.  

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Eisai Inc, GSK, Karyopharm Therapeutics, and Merck.

Program Schedule — Central Time
6:30 PM – 7:00 PM — Registration and Dinner
7:00 PM – 9:00 PM — Educational Meeting

Target Audience
This activity is intended for medical and gynecologic oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of ovarian and endometrial cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

• Understand available clinical research findings with PARP inhibitors as maintenance therapy after first-line platinum-based chemotherapy for patients with advanced ovarian cancer (OC), and provide appropriate counsel regarding personalized treatment recommendations.
• Assess available clinical trial data with and newly adapted indications for FDA-endorsed PARP inhibitors for patients with recurrent, platinum-sensitive and multiregimen-refractory OC in order to optimally and appropriately incorporate these agents into current treatment algorithms.
• Evaluate the biological rationale for and published research data with PARP inhibitors in combination with other systemic therapies, and consider the current and future clinical and research implications of these findings for OC management.
• Appreciate available clinical research findings with anti-PD-1/PD-L1 antibodies in combination with chemotherapy as first-line treatment for advanced or recurrent endometrial cancer (EC), and consider the current and future role of this novel strategy in the care of patients with microsatellite instability-high/mismatch repair-deficient and microsatellite-stable/mismatch repair-proficient disease.
• Recognize available data with anti-PD-1/PD-L1 antibodies in combination with agents targeting the VEGF pathway, and select patients with metastatic EC to receive this novel approach.
• Understand the biological rationale for and available data with PARP inhibitors in combination with immune checkpoint inhibitor therapy for patients with advanced or metastatic EC.
• Evaluate published clinical research findings documenting the efficacy of HER2-targeted agents and regimens in patients with HER2-overexpressing EC, OC and other gynecologic cancers, and consider the role of various approaches in the management of these diseases.
• Describe the scientific justification for, published research data with and ongoing studies of novel agents and strategies for OC and EC, and effectively prioritize clinical trial opportunities for eligible patients.

CME Credit Form
A CME credit link will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Backes — Advisory Committees and Consulting Agreements: AstraZeneca Pharmaceuticals LP, BioNTech SE, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, EMD Serono Inc, GSK, ImmunoGen Inc, Merck. Dr Mirza — Advisory Committees: Allarity Therapeutics, Karyopharm Therapeutics; Consulting Agreements: Allarity Therapeutics, AstraZeneca Pharmaceuticals LP, BIOCAD, BioNTech SE, Boehringer Ingelheim Pharmaceuticals Inc, Daiichi Sankyo Inc, Eisai Inc, Genmab US Inc, GSK, ImmunoGen Inc, Incyte Corporation, Karyopharm Therapeutics, Merck, Mersana Therapeutics Inc, MSD, Novartis, Regeneron Pharmaceuticals Inc, Roche Laboratories Inc, Seagen Inc, Takeda Pharmaceuticals USA Inc, Zai Lab; Contracted Research: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Daiichi Sankyo Inc, Deciphera Pharmaceuticals Inc, GSK, Merck, Mersana Therapeutics Inc, Nuvation Bio, Tesaro, A GSK Company; Stock Options/Stock — Public Company: Karyopharm Therapeutics. Dr Salani — Advisory Committees: Eisai Inc, GSK, ImmunoGen Inc, Karyopharm Therapeutics, Merck, Regeneron Pharmaceuticals Inc, Seagen Inc. Dr Slomovitz — Consulting Agreements: Aadi Bioscience, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, GSK, ImmunoGen Inc, Merck, Novocure Inc; Speakers Bureau: Seagen Inc; Nonrelevant Financial Relationship: GOG Foundation Inc.

MODERATOR — Dr Secord — Clinical Trial Steering Committees (Uncompensated): Aravive Inc (AXLerate trial), CanariaBio Inc (FLORA-5 trial, QPT-ORE-004 trial), F Hoffmann-La Roche Ltd (AtTEnd trial); Contracted Research: AbbVie Inc, Aravive Inc, AstraZeneca Pharmaceuticals LP, CanariaBio Inc, Clovis Oncology, Eisai Inc, Ellipses Pharma, Genentech, a member of the Roche Group, GSK, I-Mab Biopharma, ImmunoGen Inc, Karyopharm Therapeutics, Merck, Mersana Therapeutics Inc, OncoQuest Inc, Seagen Inc, VBL Therapeutics, Zentalis Pharmaceuticals; Data and Safety Monitoring Board/Committee: CanariaBio Inc.

CONTRIBUTING GENERAL MEDICAL/GYNECOLOGIC ONCOLOGISTS
Eric H Lee, MD, PhD — No relevant conflicts of interest to disclose. Priya Rudolph, MD, PhD — Advisory Committees and Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Daiichi Sankyo Inc, Gilead Sciences Inc, Pfizer Inc; Speakers Bureaus: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Gilead Sciences Inc, Lilly, Pfizer Inc, Puma Biotechnology Inc, Seagen Inc, Stemline Therapeutics Inc. Lindsay J Willmott, MD — Advisory Committee: OncoC4; Data and Safety Monitoring Board/Committee: Merck; Speakers Bureaus: AstraZeneca Pharmaceuticals LP, Eisai Inc, ImmunoGen Inc, Merck, Seagen Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Eisai Inc, GSK, Karyopharm Therapeutics, and Merck.

Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Phone: (312) 922-4400

Meeting Room
Grand Ballroom (Level 2)

Directions
The Hilton Chicago hotel is located just 5 minutes (2.5 miles) north of the McCormick Place convention center, where the ASCO Annual Meeting is taking place.